Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxorubicin
Drug ID BADD_D00723
Description Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Indications and Usage Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Marketing Status approved; investigational
ATC Code L01DB01
DrugBank ID DB00997
KEGG ID D03899
MeSH ID D004317
PubChem ID 31703
TTD Drug ID D07VLY
NDC Product Code 12543-3209; 70121-1218
UNII 80168379AG
Synonyms Doxorubicin | Farmiblastina | Ribodoxo | Rubex | Adriamycin | Adriblastin | Adriblastine | Adriblastina | Adriablastine | Adriablastin | Adrimedac | DOXO-cell | DOXO cell | Urokit Doxo-cell | Urokit Doxo cell | Doxolem | Doxorubicin Hexal | Doxorubicin Hydrochloride | Hydrochloride, Doxorubicin | Doxorubicin NC | Doxorubicina Ferrer Farm | Doxorubicina Funk | Doxorubicina Tedec | Doxorubicine Baxter | Doxotec | Myocet | Onkodox
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 23214-92-8
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site reaction08.02.03.014; 12.07.03.0150.000302%
Insomnia19.02.01.002; 17.15.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.0330.002071%Not Available
Intertrigo23.03.04.0280.000504%Not Available
Intestinal dilatation07.02.02.0100.000224%Not Available
Intestinal ischaemia24.04.08.001; 07.15.02.0010.000280%Not Available
Intestinal obstruction07.13.01.0020.000560%Not Available
Intestinal perforation07.04.06.0020.000168%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.0040.000280%Not Available
Jaundice cholestatic09.01.01.005--Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.000392%Not Available
Keratitis06.04.02.002--
Ketosis14.01.01.001--Not Available
Laboratory test abnormal13.18.01.001--Not Available
Lacrimation increased06.08.02.004--
Large intestine perforation12.02.03.005; 07.04.06.0050.000168%
Laryngeal oedema23.04.01.005; 22.04.02.001; 10.01.05.0030.000112%
Laryngitis22.07.03.001; 11.01.13.001--
Left ventricular failure02.05.02.0010.000112%Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.000504%
Leukaemia16.01.03.001; 01.10.03.001--
Leukocytosis01.02.01.0020.000560%
Leukoderma23.05.02.001--Not Available
Leukopenia01.02.02.0010.002462%Not Available
Leukoplakia oral07.05.01.0090.000392%Not Available
Liver function test abnormal13.03.04.030--Not Available
Local reaction08.01.03.012--Not Available
Loss of consciousness17.02.04.004--Not Available
Lung consolidation22.01.02.0100.000112%Not Available
Lung disorder22.02.07.0010.000839%Not Available
The 10th Page    First    Pre   10 11 12 13 14    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene